




# Mercaptopurine

NOT RECOMMENDED AS AN  
ESSENTIAL MEDICINE

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

		<b>EMLc</b>	ATC codes: <b>L01BB02</b>
<b>Indication</b>	Unspecified malignant neoplasms of ill-defined or unspecified sites	ICD11 code: <b>2D9Z</b>	
<b>INN</b>	Mercaptopurine		
<b>Medicine type</b>	Chemical agent		
<b>List type</b>	Complementary (EML) (EMLc)		
<b>Formulations</b>	Oral > Solid: 50 mg tablet		
<b>EML status history</b>	First added in 1984 ( <a href="#">TRS 722</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Removed in 2015 ( <a href="#">TRS 994</a> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
<b>Wikipedia</b>	<a href="#">Mercaptopurine</a> 		
<b>DrugBank</b>	<a href="#">Mercaptopurine</a> 		

## Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of mercaptopurine was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for mercaptopurine for more information.

